Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib for Unresectable Advanced Chondrosarcoma
NCT04260113Completed
- Sponsor
- Peking University People's Hospital
- Start
- Oct 2019
- Primary completion
- Jan 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of Rivoceranib in chondrosarcoma, sponsored by Peking University People's Hospital. Primary endpoint: Progression-Free Survival at 6 months. Started Oct 2019; status: completed.
02
Drugs
Rivoceranib
03
Conditions
chondrosarcoma
Beyond the preview
Go deeper on NCT04260113.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04260113.